[Left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy treated with percutaneous

Socorro Rivera1, Marta Sitges, Manel Azqueta

  • 1Institut d'Investigacions Biomèdiques August Pi i Sunyer. Institut de Malalties Cardiovasculars. Hospital Clínic. Universidad de Barcelona. Barcelona. España.

Insights

Alcohol septal ablation for hypertrophic obstructive cardiomyopathy reduces outflow tract obstruction, leading to significant left ventricular remodeling. This includes increased chamber size and regression of hypertrophy, suggesting long-term clinical improvement.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiac Imaging

Background:

  • Hypertrophic obstructive cardiomyopathy (HOCM) is characterized by left ventricular hypertrophy (LVH) potentially exacerbated by outflow tract obstruction.
  • Alcohol septal ablation is a therapeutic option for HOCM to reduce obstruction.

Purpose of the Study:

  • To assess the impact of reducing left ventricular outflow tract (LVOT) obstruction via alcohol septal ablation on LVH and remodeling in HOCM patients.
  • To evaluate the changes in LV dimensions, wall thickness, and LVOT pressure gradients over time post-ablation.

Main Methods:

  • A cohort of 20 HOCM patients undergoing alcohol septal ablation was studied.
  • Doppler echocardiography was performed at baseline, immediately post-ablation, and at 3 and 12 months follow-up.
  • Measurements included LV dimensions, wall thickness, and LVOT pressure gradients.

Main Results:

  • Alcohol septal ablation significantly reduced LVOT pressure gradients immediately post-procedure.
  • At 12 months, significant increases in LV end-diastolic and end-systolic diameters and volumes were observed.
  • A reduction in septal and posterior wall thickness occurred, indicating regression of hypertrophy.

Conclusions:

  • Relief of LVOT obstruction through alcohol septal ablation promotes LV remodeling and hypertrophy regression in HOCM patients.
  • These mid- to long-term changes suggest potential for clinical benefit and improved patient outcomes.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...